William Aird/X
Sep 17, 2025, 10:54
Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
William Aird, Professor of Medicine at Harvard Medical School, posted on X:
”POWERING UP RBCs
Mitapivat is an oral allosteric activator of pyruvate kinase → ↑ glycolytic ATP.
FDA-approved for PK deficiency anemia; in trials for sickle cell disease and thalassemia.
More ATP = healthier, longer-lived red cells across hemolytic disorders.”
Stay updated with Hemostasis Today.
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood
-
Feb 16, 2026, 14:44Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES